Nfocus CardioVasc stent-graft
This article was originally published in Clinica
Executive Summary
Nfocus Neuromedical has CE marked its CardioVasc stent-graft and delivery system for sale in Eurple. The minimally-invasive device treats patients with perforated vessels, coronary artery aneurysms or saphenous vein graft lesions caused during a previous coronary bypass. Palo Alto, California-based Nfocus expects further regulatory approvals over the next 12 months. The CardioVasc is delivered during a minimally-invasive catheter procedure. It is not yet approved in the US.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.